Abstract: The invention relates to the sulfonyl esters of the general formula R1—COO—SO2—Z—R2, wherein Z, R1 and R2 are defined as in claim 1. The invention further relates to the use of one of the inventive compounds for modifying the kinetics of the enzymatic effect of catalase. A method for measuring a concentration in living and/or active microorganisms in a liquid sample (3) by means of the development of oxygen from hydrogen peroxide is also based on the above-mentioned modification. An inventive compound is admixed in a container (1) to the sample, said compound inactivates the enzymatic effect of endogenous catalase without substanially inactivating the enzymatic effect of the intracellular catalase of microorganisms. Hydrogen peroxide is added and immediately afterwards the pressure present in the sample container is briefly equalized with the atmosphere, the container is closed in a gas-tight manner (2) during a predetermined reaction time and the pressure in the container is measured (9, 10, 11).

Abstract: Photoacid generator salts comprising photoactive cationic moieties and segmented, highly fluorinated-hydrocarbon anionic moieties are disclosed which provide high photoacid strength and can be tailored for solubility and polarity. The present invention further relates to photoacid generators as they are used in photoinitiated acid-catalyzed processes for uses such as photoresists for microlithography and photopolymerization.

Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

Abstract: The invention relates to a process for the preparation of alkylarylsulfonates by a) reaction of a C4-olefin mixture over a metathesis catalyst for the preparation of an olefin mixture comprising 2-pentene and/or 3-hexene, and optional removal of 2-pentene and/or 3-hexene, b) dimerization of the 2-pentene and/or 3-hexene obtained in stage a) over a dimerization catalyst to give a mixture containing C10-12-olefins, and optional removal of the C10-12-olefins, c) reaction of the C10-12-olefin mixtures obtained in stage b) with an aromatic hydrocarbon in the presence of an alkylating catalyst to form alkylaromatic compounds, where, prior to the reaction, additional linear olefins may be added, d) sulfonation of the alkylaromatic compounds obtained in stage c), and neutralization to give alkylarylsulfonates, where, prior to the sulfonation, linear alkylbenzenes may additionally be added, e) optional mixing of the alkylarylsulfonates obtained in stage d) with linear alkylarylsulfonates.

Abstract: Phosphonium salts represented by the general formula (I) wherein R1 and R2 each represents a phenyl group which may be substituted by a lower alkyl group, R3 represents a phenylene group which may be substituted by a lower alkyl group, R7 and R8 each represents a hydrogen atom or a hydrocarbon group having 1 to 12 carbon atoms which may be substituted and R9 represents a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms which may be substituted; processes for producing the same and uses for the same; phosphines providing the same, and processes for producing said phosphines.

Abstract: The present invention provides a sulfonate of the formula (I): wherein Q1, Q2, Q3, Q4 and Q5 each independently represent hydrogen, alkyl having 1 to 16 carbon atoms, alkoxy having 1 to 16 carbon atoms, halogen, aryl having 6 to 12 carbon atoms, aralkyl having 7 to 12 carbon atoms, cyano, sulfide, hydroxy, nitro or a group of the formula (I?) —COO—X—Cy1??(I?) wherein X represents alkylene and at least one —CH2— in the alkylene may be substituted by —O— or —S—, and Cy1 represents alicyclic hydrocarbon having 3 to 20 carbon atoms, and A+ represents a counter ion, with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is the group of the formula (I?).

Abstract: The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell, as well as inhibiting lymphocyte traffic through the lymph nodes. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule.

Abstract: The present invention relates to a process for the production of alkanesulfonic acid. More particularly, the present invention relates to a process for the production of alkanesulfonic acid from alkyl mercaptan effluents generated in chemical industries. The process of the invention comprises the oxidation of the entire alkyl mercaptan generated as an effluent in the chemical industries to serve two concomitant purposes: (1) complete removal of obnoxious odor, and (2) value addition by the production of alkanesulfonic acids selectively in quantitative yields.

Abstract: Disclosed herein is a process for preparing 4-(2-sulfoethylcyclohexane)-1,2-diol sodium salt, at ambient condition and in the presence of a buffer and an initiator, from vinylcyclohexane-1,2-diol. Also disclosed is a process for preparing 3-(2-sulfoethyl) hexanedioic acid, sodium salt by oxidizing 4-(2-sulfoethylcyclohexane)-1,2 diol sodium salt with hydrogen peroxide in the presence of tungstic acid.

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising novel crystalline sibutramine methanesulfonate hemihydrate of formula (I).

Abstract: The invention relates to a method for the production of ?-aminoalkylsulphonic acids of general formula (I), where R1 and R2=optionally substituted alkyl groups with 1 20 C atoms and n=a whole number from 2 6, whereby an amine of formula (II), where R1 and R2 have the above meanings is reacted with an alkyl dihalide of formula (III), where n has the above meaning and X1 and X2=chlorine or bromine, with addition of alkali hydroxide at a pH of 8 10. The pH is then adjusted to a value of 0 1, by addition of a hydrohalic acid and excess alkyl dihalide is separated off, before the reaction solution is adjusted to a pH of 6 7.5 with alkali liquor, alkali sulphite is added and the product (I) formed at elevated temperate.

Abstract: The invention concerns a process for the continuous drying of a hydrocarbon stream and comprises contacting the hydrocarbon stream with an ionic, liquid drying agent of a salt of a fluorinated sulphonic acid.

Abstract: A process for preparing solutions of sulfonated arylphosphines comprising reacting arylphosphines with oleum, diluting the sulfonation mixture with water, extracting the diluted sulfonation mixture with a solution of a water-insoluble organic solvent, reacting the organic phase with a solution of an inorganic base in water, adjusting the resulting aqueous solutin of sulfonated arylphosphines to a pH of up to 3 by addition of an acid, and passing an inert gas stream through the aqueous solution comprising sulfonated arylphosphines until sulfur is no longer liberated from the aqueous solution of sulfonated arylphosphines.

Abstract: The invention relates to a process for the preparation of a low-base number calcium sulfonate that is essentially chloride free. The process involves preparing a sulfonic acid solution by adding a solvent to sulfonic acid, removing dissolved or entrained SO2 or SO3, mixing the solution with a specific amount of water and calcium hydroxide, heating the mixture, separating out excess calcium hydroxide and calcium salts from the mixture, and recovering solvent and oil to capture the calcium sulfonate product.

Abstract: This invention relates to salts of guanidine derivatives of formula R—X—C(═NH)NH3+Z−, wherein X represents a valence bond, —CH2—NH—, —CH2—NH—NH— or —CH═N—NH—; R represents a linear or branched C1-C30 alkyl, C3-C20 cycloalkyl, adamantyl, norbornyl, tricyclodecyl, benzyl, furyl, pyridyl, anthracyl, naphthyl, phenanthryl, perinaphthyl or quinuclidinyl residue, which can be substituted by one or more hydroxyl groups, C1-C4 alkoxy groups, C1-C4 alkyl groups and/or one or more halogen atoms or one or more amino groups; Z represents O—CO—Y, O—S(O)2—Y, or O—P(O)(OH)—Y; and Y represents a linear or branched C1-C12 alkyl, C3-C8 cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C1-C4 alkoxy groups, C1-C4 alkyl groups and/or one or more halogen atoms or one or more amino groups.

Abstract: The invention relates to the sulfonyl esters of the general formula R1—COO—SO1-Z-R2, wherein Z, R1 and R2 are defined as in claim 1. The invention further relates to the use of one of the inventive compounds for modifying the kinetics of the enzymatic effect of catalase. A method for measuring a concentration in living and/or active microorganisms in a liquid sample (3) by means of the development of oxygen from hydrogen peroxide is also based on the abovementioned modification. An inventive compound is admixed in a container (1) to the sample said compound inactivates the enzymatic effect of endogenous catalase without substanially inactivating the enzymatic effect of the intracellular catalase of microoganisms. Hydrogen peroxide is added and immediately afterwards the pressure present in the sample container is briefly equalized with the atmosphere, the container is closed in a gas-tight manner (2) during a predetermined reaction time and the pressure in the container is measured (9,10,11).

Abstract: The present invention relates to a process for the production of alkanesulfonic acid. More particularly, the present invention relates to a process for the production of alkanesulfonic acid from alkyl mercaptan effluents generated in chemical industries. The process of the invention comprises the oxidation of the entire alkyl mercaptan generated as an effluent in the chemical industries to serve two concomitant purposes: (1) complete removal of obnoxious odour, and (2) value addition by the production of alkanesulfonic acids selectively in quantitative yields.

Abstract: This invention relates to high purity hydrogen ion buffers and in particular amino-organosulfonic acid zwitterionic compositions having low metal content. The concentration of any single metal in the composition is no greater than about 500 ppb, and ideally is less than about 20 ppb.

Abstract: The present invention provides a sulfonate of the formula (I): 1

Abstract: The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: Phenylene-bis-benzimidazole-tetrasulfonic acid disodium salt which is largely free from impurities can be prepared by reacting o-phenylenediamine with terephthalic acid and chlorosulfonic acid in the presence of strong acids with a reaction time of 10 to 15 hours.

Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

Abstract: The present invention is a demulsifying and corrosion-inhibiting compound formed from the salt of an amphiphilic amine and an amphiphilic acid. In a preferred embodiment of the invention, the demulsifier may be a salt of an alkyl amine and an alkyl aryl sulfonic acid. Even more preferably, the demulsifier may be a salt of a methyl, di-cocoyl amine and an alkyl aryl sulfonic acid. According to another embodiment of the invention, an organic system may be demulsified by mixing the salt of an alkyl amine and an alkyl sulfonic acid with the system to be demulsified.

Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.

Abstract: Derivatives of C2-substituted indan-1-ol compounds, processes for their preparation and their use are disclosed. In particular, the invention relates to compounds of the formula I and to their physiologically acceptable salts and physiologically functional derivatives. The compounds are suitable, for example, for use as anorectics.

Abstract: A process for producing organic sulfur acid or a salt thereof of the present invention allows an organic substrate to react with a sulfur oxide in the presence of a metallic compound catalyst and in the absence of N-hydroxy and N-oxo cyclic imide compounds and thereby yields a corresponding organic sulfur acid or a salt thereof. Such organic substrates include, for example, (a) homocyclic or heterocyclic compounds having a methylene group, (b) compounds having a methine carbon atom, (c) compounds having a methyl group or methylene group at the adjacent position to an unsaturated bond, (d) non-aromatic heterocyclic compounds having a carbon-hydrogen bond at the adjacent position to a hetero atom, and (e) straight-chain alkanes. The sulfur oxide includes, for example, sulfur dioxide. This production process can efficiently produce an organic sulfur acid or a salt thereof under mild conditions.

Abstract: A composite metal polybasic salt containing a trivalent metal and magnesium as metal components and having a novel crystal structure, and a method of preparing the same. The invention further deals with a composite metal polybasic salt which has anion-exchanging property, which by itself is useful as an anion-exchanger, capable of introducing anions suited for the use upon anion-exchange, and finds a wide range of applications, and a method of preparing the same. The composite metal polybasic salt has a particular chemical composition and X-ray diffraction peaks, and further has a degree of orientation (Io) of not smaller than 1.5.

Abstract: A group of new compounds, N-(all-trans-Retinoyl)-L-cysteic acid, N-(13-cis-Retinoyl)-L-cysteic acid, N-(all-trans-Retinoyl)-L-cysteinesulfinic acid, N-(13-cis-Retinoyl)-L-cysteinesulfinic acid, N-(all-trans-Retinoyl)-L-homocysteic acid, N-(13-cis-Retinoyl)-L-homocysteic acid, and sodium salts of these compounds, including sodium salts of their esters and amides, is shown to exhibit therapeutic effects per se, and which compounds in combination with cytotoxic compounds, such as docetaxel, paclitaxel, doxorubicin and mitoxantrone, exhibit a synergistic effect. These compounds make it possible to manufacture new formulations of poorly soluble pharmaceutical compounds, and the present invention discloses a process of manufacturing water-soluble formulations of such compounds, exemplified by docetaxel, and paclitaxel, exhibiting enhanced pharmacological activity, and formulations of water-soluble pharmaceuticals exemplified by doxorubicin and mitoxantrone, exhibiting improved therapeutic efficacy.

Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

Abstract: Embodiments of the invention relate to C2-substituted indan-1-ols and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention may include compounds of formula I in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.

Abstract: Water-soluble sulfonated organophosphorus compounds are purified by at least partially removing contaminating sulfite values therefrom, by decreasing the pH of a solution of such sulfonated organophosphorus compounds to a value of less than or equal to 4, and maintaining the pH of the solution at this value of 4 or less for such period of time as to reduce the weight concentration of sulfite in the solution to less than 100 ppm; the organophosphorus compounds thus purified are well suited for the two-phase cocatalysis of a wide variety of organic reactions.

Abstract: Diaryliodonium salts are disclosed, as well as a method for preparing them, in which one of the aryl groups bonded to the positively-charged iodine ion contains a methyl substituent, and the other one contains a hydroxyl-substituted alkoxy group. The salts are synthesized from (o, m, or p)-iodotoluene, as opposed to iodobenzene, and therefore do not pose a carcinogenic risk. In addition, the present salts are unexpectedly more soluble in most organic solvents, as well as in nonpolar monomers, than the corresponding benzene catalysts. The salts are useful as cationic photoinitiators, cationic thermal initiators (often combined with a cocatalyst, e.g. copper), and as starting materials in the synthesis of urethane-containing iodonium salts.

Abstract: The invention relates to a method for producing sulfonated aryl phosphines by reacting aryl phosphines with oleum. After reacting the aryl phosphines with oleum, the sulfonation mixture is firstly diluted with water and an inert gas stream is then fed through the diluted sulfonation mixture until SO2 is no longer released from the diluted sulfonation mixture. Afterwards, the sulfonation mixture is subsequently processed in a usual manner. The invention also relates to a method for producing solutions of sulfonated aryl phosphines by reacting the aryl phosphines with oleum, diluting the sulfonation mixture with water, extracting the aqueous solution using an organic solution consisting of an amine, and subsequently carrying out a reextraction using an aqueous solution having an inorganic base.

Abstract: The present invention is a demulsifying and corrosion-inhibiting compound formed from the salt of an amphiphilic amine and an amphiphilic acid. In a preferred embodiment of the invention, the demulsifier may be a salt of an alkyl amine and an alkyl aryl sulfonic acid. Even more preferably, the demulsifier may be a salt of a methyl, di-cocoyl amine and an alkyl aryl sulfonic acid. According to another embodiment of the invention, an organic system may be demulsified by mixing the salt of an alkyl amine and an alkyl sulfonic acid with the system to be demulsified.

Abstract: A process for isolating one or more enantiomer components from a mixture of enantiomers through co-crystallization is disclosed.

Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

Abstract: The photoacid generator according to the present invention is represented by the general formula (1): wherein R1 and R2 are respectively H, OH or alkyl or alkoxy group of C1-5 and are the same or different, n is an integer from 1 to 3, and Ar1 is a naphthalene unit. The photosensitive resin used in a composition of the invention is represented by the general formula (2): wherein X is a tetravalent aromatic or aliphatic organic radical, Y is a bivalent aromatic or aliphatic organic radical, and R3 and R4 independently are H or a monovalent aliphatic organic protecting group removable by acid.

Abstract: This invention provides methods and catalyst systems for catalyzing enantioselective oxidation reactions, including cyclization reactions and enantioselective oxidation reactions of secondary alcohols and other similarly reactive organic substrates. Use of the methods and catalyst systems for kinetic resolution of racemic mixtures of secondary alcohols is also described.

Abstract: Novel perfluoroalkyl-substituted mono-, di- and poly-amide compounds which are reaction products of a mono-, di- or polyamine of 60 to 2000 molecular weight with a perfluoroalkyl substituted unsaturated acid or its corresponding lower alkyl ester and optionally a non-fluorinated amino-reactive compound such as an acid, ester, anhydride, epichlorohydrin, isocyanate or urea, are useful as internally or externally applied paper sizes to impart oil and grease resistance to paper, and as oil proofing coatings on textiles, wood, masonry and the like, or as high-performance surface active agents.

Abstract: A method for enhancing the purity of a desired compound comprising: Step (a) treating a crude reaction product which contains at least one desired compound, unreacted starting materials and/or byproducts with at least one bifunctional quenching agent that is capable of selective covalent reaction with unwanted byproducts, or excess reagents; Step (b) allowing the quenching agent to covalently react with unreacted starting materials and/or byproducts to afford a derivatized compound of the quenching agent: and Step (c) isolating the desired compound is described as well as novel quenching agents and methods for their use in the rapid purification of synthetic intermediates and products in synthesis, combinatorial chemistry, and automated organic synthesis.

Abstract: The invention provides a process for covalently coupling organic compounds which comprises reacting an aromatic ring compound having a halogen or halogen-like substituent at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitabIe base. The invention also provides useful arylboron intermediates.

Abstract: Disclosed is a process for the preparation of trifluoromethanesulfonic acid anhydride by the steps of (1) forming a mixed anhydride comprising a trifluoromethanesulfonyl acyl residue and a carboxyl residue by contacting trifluoromethanesulfonic acid or a derivative thereof with a carboxyl compound selected from ketene, dialkyl ketenes, carboxylic acids, and derivatives of carboxylic acids and (2) subjecting the mixed anhydride to reactive distillation wherein the mixed anhydride undergoes disproportionation to produce triflic anhydride and a higher boiling carboxylic acid anhydride.

Abstract: Disclosed is a method of producing an optically active &bgr;-hydroxy sulfonic acid compound comprising hydrogenating a &bgr;-keto sulfonic acid compound represented by formula 1: where R1 represents an alkyl or a phenyl group, which may be substituted, and R2 represents sodium or an alkyl group, in an acidic solvent, in the presence of an asymmetric catalyst comprising a complex of bivalent Ru, having 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl as a ligand, to produce a compound represented by formula 2: where R1 and R2 are as defined above, and * designates an asymmetric carbon atom.

Abstract: The invention relates to the use of oximesulfonic acid esters of formula I 1

Abstract: The present invention relates to chromotropic nitrone spin trapping agents, methods of making these agents, compositions comprising same, and methods of their use. In particular, azulenyl nitrones of the present invention are effective agents for trapping free radical species and find use as efficient antioxidants in physicochemical and biological systems. Accordingly, the invention also relates to spin adducts formed from the combination of azulenyl nitrones with free radicals. The compounds of the present invention are readily prepared from available starting materials and find further use in assays and in a number of diagnostic, prophylactic and therapeutic applications, including but not limited to the alleviation, modulation and inhibition of the negative effects of carbon-centered or oxygen-centered radical species and other products of oxidation. Moreover, the combination adducts may be colorimetrically detected and, optionally, isolated and characterized to obtain valuable information (e.g.

Abstract: The invention relates to novel S-(4-biphenyl)-thiosulfuric acids and their salts, to a method for producing them from S-(4-biphenyl)-thiosulfinic acids and their salts, and to a method for producing 4-mercaptobiphenyls from the S-(4-biphenyl)-thiosulfuric acids and their salts.

Abstract: A process for preparing phenoxyphenylsulfonyl halides, which are useful intermediates for the preparation of matrix metalloproteinase inhibitors.

Abstract: A process for the preparation of phosphabenzene compounds of the formulae I and II where R1 to R6, independently of one another, are hydrogen, COOM SO3M, NR3X, NR2, OR, COOR or SR, where M is hydrogen, NH4 or an alkali metal, X is an anion, R is hydrogen, C1-6-alkyl, or C1-12-alkyl, C6-12-aryl, C7-12-aralkyl or C3-6-heterocycloalkyl having 1 to 3 heteroatoms which may be substituted by the above radicals or linked to form fused rings, and —W— is a bridge comprising a covalent bond, an oxo group, a sulfur group, an amino group, a di-C1-6-alkylsilicon group or a C1-16-radial, which may be part of one or more linked cyclic or aromatic rings and may be interrupted by 1 to 3 heteroatoms, where the phosphabenzene ring o- or m-position not bonded to the bridge may carry one of the radicals R1 to R6, with the exception of bis-3,3′-(2,4,6-triphenyl-3-phosphabenzene)-1,1-biphenyl, by reacting corresponding pyrilium salts with PH3 in the presence of a catalytic amount of acid and in

Abstract: Certain simple chemical agents, referred to herein as nitrone related therapeutics or “NRTs”, when administered to a patient susceptible to neovascularization (angiogenesis), can intervene and inhibit the disease's progress. Methods for therapeutically and prophylactically inhibiting angiogenesis by administering one or more NRTs are disclosed as are pharmaceutical compositions for use in such methods of treating. NRTs useful in these compositions and therapeutic methods are also disclosed.

Abstract: Phosphabenzene compounds of the formulae I and II where R1 to R6 are identical or different and are, for example, hydrogen, are prepared by reacting corresponding pyrylium salts with PH3 in the presence or absence of a solvent or diluent. The pyrylium salts are combined with PH3 at above 0° C. and reacted at a temperature in the range from 0° C. to 200° C. and a pressure above 1 bar without addition of an acid catalyst or a base.